In the last 10–15 years, the introduction of biological therapies, such as TNF-α, IL-12/23, and IL-17 inhibitors in psoriasis and IL-6, CD20, TNF-α, and CD80/86 inhibitors in RA, is expected to influence the rate of atherothrombotic complications in patients with psoriasis and RA [8,11,47]. This evidence concerns the gene IL17A and psoriasis.